Business Wire Feed
UnitedHealthcare Community Plan of D.C. Earns NCQA LTSS Distinction
--(BUSINESS WIRE)--UnitedHealthcare Community Plan of D.C. has earned the Long-Term Services and Supports (LTSS) Distinction by the National Committee for Quality Assurance (NCQA). NCQA is a private, non-profit organization dedicated to improving health care quality. more...
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
Dexcom has announced a new continuous glucose monitoring system designed for people using basal insulin, oral therapies or GLP-1 receptor agonists1. The new system will be available shortly. Dexcom Flex provides real-time glucose data, personalised more...
New Real-World Case Series Examines Re-Induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice
Re-induction with ADSTILADRIN resulted in complete responses in 31% of initial non-responders with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (n=13) Findings suggest re-induction may allow additional patients to achieve a complete response in a more...
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center
Compact, vault-integrated platform selected through a competitive European tender will bring proton therapy to patients across Southern Italy.LITTLETON, Mass.--(BUSINESS WIRE)--#MevionFIT--Mevion Medical Systems, the global leader in compact proton therapy, today announced that it has been more...
AVL Hosts Virtual Salon Suite Exploring How IVF Research Inspired a New Era of Science-Backed Skincare
NEW YORK--(BUSINESS WIRE)--#AVLaboratories--AV Laboratories, the science-backed skincare brand redefining the intersection of science, skincare, and longevity, will host an exclusive virtual salon suite on Thursday, May 21, 2026 at 11:00 AM EST for editors, media, more...
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tokyo strain of BCG (Tokyo-172 BCG) versus TICE BCG in BCG-naïve high-grade non-muscle invasive bladder cancer more...
Dr. Reddy’s Laboratories Launches its Generic Semaglutide Injection in Canada
The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s readiness to serve Canadian patients Dr. Reddy’s is the first company to receive more...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial Two new indications bring AstraZeneca and Daiichi Sankyo’s ENHERTU into curative-intent setting, reinforcing more...
Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer
Approved for use before surgery based on DESTINY-Breast11 phase 3 trial or following surgery based on DESTINY-Breast05 phase 3 trial Two new indications bring Daiichi Sankyo and AstraZeneca’s Enhertu into curative-intent setting, reinforcing its role more...
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
First-ever human clinical trial of a xenoheart intended to support potential registration through the submission of a Biologics License Application to the U.S. FDASILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: more...
Novanta to Present at Jefferies Global Healthcare Conference on Thursday, June 4, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Jefferies Global Healthcare Conference more...
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy Median overall survival of 12.3 months in a heavily pretreated population with poor prognostic features, including ALBI grade 2 more...
Novanta to Present at Baird 2026 Global Consumer, Technology & Services Conference on Wednesday, June 3, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Baird 2026 Global Consumer, more...
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
First approved ctDNA MRD-guided therapy reinforcing Genentech’s commitment to innovation and practice-changing precision medicine New treatment approach enables healthcare professionals to tailor treatment with the goal of improving clinical benefit and reducing unnecessary intervention Approval more...
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions Solidifies Natera’s Treatment on MRD (TOMR) approach as the new standard of care in MIBC, enabling precision interventions for more...
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
Peer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple outcomes related to disease progression, including pancreatic more...
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
Primary results from the Phase II ARASEC trial show that NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with metastatic castration-sensitive more...
Secretome Therapeutics Announces Participation in Upcoming Summer Investor Conferences
Company to attend Jefferies, Oppenheimer, and Cantor investor conferences focused on the biopharma sectorPLANO, Texas--(BUSINESS WIRE)--#Biotech--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today more...
ER wait-times surged at Ottawa hospitals over the past three years due to provincial underfunding: CCPA report
OTTAWA--(BUSINESS WIRE)--The majority of Ontario’s 136 hospitals including facilities in Ottawa have carried operational deficits since 2022, and this puts an already precarious public system at risk, says new analysis from the Canadian Centre for more...
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual Craig-Hallum Institutional Investor Conference more...
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
WHIPPANY, N.J.--(BUSINESS WIRE)--Up to 90% of menstruators experience PMS symptoms1, many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol® in Motion, a campaign focused on helping people better understand more...
Relias Earns Second Gold Bell Seal for Workplace Mental Health
National honor from Mental Health America highlights company’s comprehensive approach to fostering a supportive workplace cultureMORRISVILLE, N.C.--(BUSINESS WIRE)--Relias, the trusted multi-solution workforce enablement partner to 13,000 healthcare organizations and 4.5 million caregivers, today announced it more...
Valar Labs Receives FDA Breakthrough Device Designation for Vesta Bladder Risk Stratify Dx
Designation recognizes the product’s potential to address a critical unmet need in bladder cancer prognosis PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, an AI precision oncology company developing diagnostics that predict cancer treatment response from routine pathology more...
Jamieson Wellness Inc. Announces Senior Credit Facilities Refinancing
Amended Credit Agreement Provides up to $800 Million of AvailabilityTORONTO--(BUSINESS WIRE)--Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX: JWEL) today announced an amendment and restatement of its existing senior credit facilities pursuant to a more...
Cizzle Brands Corporation Announces the Launch of CWENCH Hydration™ at Save-On-Foods Across Western Canada
The better-for-you sports drink rolls out to more than 170 Save-On-Foods stores, further building CWENCH Hydration’s Canadian grocery footprint.TORONTO--(BUSINESS WIRE)--Cizzle Brands Corporation (Cboe Canada: CZZL; OTCQB: CZZLF; Frankfurt: 8YF) (“Cizzle Brands” or the “Company”), the more...